Top of this page
Skip navigation, go straight to the content Newsroom UCB U.S. News


  • Advancing Our Green Strategy for the Future

    Posted by Katelyn Snider, U.S. Communications and Public Affairs
    We believe our ability to continue to innovate and create value for patients now and in the future will increasingly depend on our positive contributions to environmental sustainability.

    Read more

  • Like
  • Press Release: UCB to provide additional information to the U.S. FDA regarding midazolam nasal spray submission


    Brussels (Belgium) & Atlanta, Georgia (U.S.) - April 1, 2019:
    UCB announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter requesting additional information to complete the review of the New Drug Application for midazolam nasal spray, a rescue treatment for acute repetitive seizures (ARS, also known as seizure clusters) in patients with epilepsy. UCB acquired the rights to midazolam nasal spray from Proximagen in June 2018.

    Read more

  • Like